JP2005534614A - アルツハイマー病治療のための置換アミノカルボキサミド - Google Patents

アルツハイマー病治療のための置換アミノカルボキサミド Download PDF

Info

Publication number
JP2005534614A
JP2005534614A JP2003558035A JP2003558035A JP2005534614A JP 2005534614 A JP2005534614 A JP 2005534614A JP 2003558035 A JP2003558035 A JP 2003558035A JP 2003558035 A JP2003558035 A JP 2003558035A JP 2005534614 A JP2005534614 A JP 2005534614A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
aryl
groups
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003558035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534614A5 (https=
Inventor
ジャゴジンスカ、バーバラ
ワルペホスキー、マーサ、エイ．
Original Assignee
イーラン ファーマスーティカルズ、インコーポレイテッド
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーラン ファーマスーティカルズ、インコーポレイテッド, ファルマシア・アンド・アップジョン・カンパニー・エルエルシー filed Critical イーラン ファーマスーティカルズ、インコーポレイテッド
Publication of JP2005534614A publication Critical patent/JP2005534614A/ja
Publication of JP2005534614A5 publication Critical patent/JP2005534614A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003558035A 2002-01-04 2003-01-06 アルツハイマー病治療のための置換アミノカルボキサミド Pending JP2005534614A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34531602P 2002-01-04 2002-01-04
US35041902P 2002-01-18 2002-01-18
PCT/US2003/000326 WO2003057721A2 (en) 2002-01-04 2003-01-06 Substituted amino carboxamides for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2005534614A true JP2005534614A (ja) 2005-11-17
JP2005534614A5 JP2005534614A5 (https=) 2006-03-16

Family

ID=26994342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558035A Pending JP2005534614A (ja) 2002-01-04 2003-01-06 アルツハイマー病治療のための置換アミノカルボキサミド

Country Status (8)

Country Link
US (1) US6962934B2 (https=)
EP (1) EP1458745A2 (https=)
JP (1) JP2005534614A (https=)
AU (1) AU2003206413A1 (https=)
BR (1) BR0306724A (https=)
CA (1) CA2472617A1 (https=)
MX (1) MXPA04006575A (https=)
WO (1) WO2003057721A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509988A (ja) * 2003-10-30 2007-04-19 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のためのヒドロキシプロピルアミド
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045551B2 (en) * 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7550481B2 (en) 2003-12-19 2009-06-23 Merck & Co., Inc. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2005070407A1 (en) * 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
CA2563639A1 (en) 2004-04-20 2005-11-03 Merck & Co., Inc. 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
JP2007533743A (ja) 2004-04-20 2007-11-22 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な１，３，５−置換フェニル誘導体化合物
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
US7714021B2 (en) * 2004-06-15 2010-05-11 Merck & Co., Inc. Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
JP2008534541A (ja) * 2005-03-30 2008-08-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換１，２−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法
NZ562314A (en) 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
US20100168070A1 (en) * 2005-08-11 2010-07-01 Niklas Heine Compounds for the treatment of alzheimer's disease
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
US20090042867A1 (en) * 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
US8222264B2 (en) 2007-07-06 2012-07-17 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
MY148558A (en) * 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500081A (ja) * 1992-06-26 1996-01-09 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白質トランスフェラーゼの阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362912A (en) 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6316440B1 (en) * 1998-07-30 2001-11-13 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
JP2003502342A (ja) * 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500081A (ja) * 1992-06-26 1996-01-09 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白質トランスフェラーゼの阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009054971, Ｎｉｚａｌ Ｓ． Ｃｈａｎｄｒａｋｕｍａｒ ｅｔ ａｌ．, "Ｐｒｅｐａｒａｔｉｏｎ ａｎｄ Ｏｐｉｏｉｄ Ａｃｔｉｖｉｔｙ ｏｆ Ａｎａｌｏｇｓ ｏｆ ｔｈｅ Ａｎａｌｇｅｓｉｃ Ｄｉｐｅｐｔｉｄｅ ２，６−Ｄｉｍｅｔｈｙｌ−Ｌ−ｔｙｒｏｓｙｌ−Ｎ−（３−ｐｈ", Ｊ． Ｍｅｄ． Ｃｈｅｍ．, 1992, Ｖｏｌ．３５， Ｎｏ．２, ｐ．２２３−２３３ *
JPN6009054972, Ｙａｅｋｏ Ｋｏｎｄａ ｅｔ ａｌ．, "Ａｌｋａｌｏｉｄ ｆｒｏｍ Ｔｈｅｒｍｏａｃｔｉｎｏｍｙｃｅｓ Ｓｐｅｃｉｅｓ", Ｃｈｅｍ． Ｐｈａｒｍ． Ｂｕｌｌ．, 1976, Ｖｏｌ．２４， Ｎｏ．１, ｐ．９２−９６ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
JP2007509988A (ja) * 2003-10-30 2007-04-19 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のためのヒドロキシプロピルアミド

Also Published As

Publication number Publication date
EP1458745A2 (en) 2004-09-22
US20030166580A1 (en) 2003-09-04
AU2003206413A8 (en) 2003-07-24
WO2003057721A3 (en) 2004-03-25
WO2003057721A2 (en) 2003-07-17
BR0306724A (pt) 2006-04-11
MXPA04006575A (es) 2004-10-04
CA2472617A1 (en) 2003-07-17
AU2003206413A1 (en) 2003-07-24
US6962934B2 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
JP2005534614A (ja) アルツハイマー病治療のための置換アミノカルボキサミド
US7358264B2 (en) Statine derivatives for the treatment of Alzheimer's disease
JP4278511B2 (ja) Ｎ−（３−アミノ−２−ヒドロキシ−プロピル）置換アルキルアミド化合物
JP2006524255A (ja) ベンズアミド２−ヒドロキシ−３−ジアミノアルカン
JP2005514330A (ja) アルツハイマー病治療のための置換アミン
JP2005538162A (ja) １，３−ジアミノ−２−ヒドロキシプロパンプロドラッグ誘導体
JP2005504022A (ja) アルツハイマー病治療のためのジアミンジオール
JP2006524258A (ja) フェナシル２−ヒドロキシ−３−ジアミノアルカン
JP2005505506A (ja) アルツハイマー病の治療に有用な大環状分子
JP2004502665A (ja) アルツハイマー病を治療する化合物
JP2005500319A (ja) アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体
US20090291970A1 (en) Substituted Aminoethers for the Treatment of Alzheimer's Disease
JP2004532894A (ja) アルツハイマー病を治療するためのアミンジオール
JP2004534064A (ja) アルツハイマー病の治療に有用な大環状分子
JP2005505517A (ja) アルツハイマー病を治療するためのアミンジオール
US7763646B2 (en) Compounds for the treatment of alzheimer's disease
JP2005536448A (ja) アミン１，２−及び１，３−ジオール化合物、及びアルツハイマー病を治療するためのその使用
JP2007509988A (ja) アルツハイマー病治療のためのヒドロキシプロピルアミド

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100514